The U.S. glaucoma market has seen notable advances in the treatment of OAG following the launches of numerous innovative drugs over the past two years, including Bausch + Lomb’s Vyzulta and Aerie Pharmaceuticals’ Rhopressa and Rocklatan, as well as the highly anticipated launch of Allergan’s bimatoprost SR in 2020. In addition to new drugs, developments have occurred in the field of MIGS in recent years. However, market access decisions for these therapies in Medicare and commercial plans influence ophthalmologists’ prescribing decisions in OAG. Therefore, it is essential for drug marketers and developers to understand how U.S. payers and ophthalmologists react to new treatments entering the highly competitive OAG market.
Geography: United States
Primary Research: Survey of 100 U.S. ophthalmologists, survey of 30 U.S. MCO PDs/MDs
Key Drugs Covered: Lumigan, Travatan Z, Combigan, Simbrinza, Alphagan P, Vyzulta, Rhopressa, Rocklatan, Xelpros, bimatoprost SR, DE-117, latanoprost, dorzolamide / timolol
Reimbursement and contracting
Access and prescribing
Opportunities and challenges for emerging therapies
U.S. Access & Reimbursement provides in-depth insight on the impact of payer policy on prescribing behavior so that clients can build their market access strategy and optimize their brand positioning. This analysis of primary market research with physician specialists and U.S. payers helps clients stay up-to-date on restriction policies, gauge payer and prescriber attitudes toward specific therapies, identify opportunities where brands can capture patient share through market access, and maximize opportunities for emerging therapies by learning how previous brands gained favorable reimbursement or why they stumbled.